Table 3.
Patient ID |
Age, years |
Sex | Type and time of treatment |
Interpretation of FDGal PET images |
Interpretation of ceCT images |
Other imaging modalities or follow-up |
T/B-ratio on FDGal PET |
---|---|---|---|---|---|---|---|
2 | 57 | M | TACE one month before PET | Multinodular disease No necrosis |
Multinodular disease No necrosis |
2.6 | |
13 | 83 | M | TACE 2 months before PET; previously 4xRFA | Response to treatment | Response to treatment | 0.2 – 0.7 | |
14 | 51 | F | RFA and TACE several times before, SBRT | Necrosis, no visible tumour | Necrosis, no visible tumour | 0.2 | |
18 | 54 | F | RFA 6 months and TACE 3.5 months before PET | Residual tumour with areas of necrosis | Residual tumour with areas of necrosis | 0.1 (necrosis) 1.4 (viable) |
|
23 | 62 | M | TACE of tumour mass in left liver lobe one week before PET | Treatment response in left liver lobe, two lesions in right liver lobe | Treatment response in left liver lobe, two lesions in right liver lobe | 0.1 (necrosis) 1.3 (viable) |
|
29 | 60 | M | RFA two years before PET | RFA-necrosis Small lesion in right liver lobe |
RFA-necrosis Small lesion in right liver lobe |
0.2 (necrosis) 1.2 (viable) |
|
34 | 62 | F | Hepatic resection 6 years before PET | No suspicious lesions | - - - | MRI: tumour in left kidney Biopsy: Renal cell carcinoma |
- - - |
37 | 57 | M | RFA 6 days before PET | No viable tumour | No viable tumour | 0.3 | |
39 | 72 | F | RFA 6 months and TACE one month before PET | Treatment response Two lesions in right liver lobe |
Several lesions (pre-treatment) | TACE was repeated | 0.4 (necrosis) 1.3 (viable) |
FDGal, 2-[18F]fluoro-2-deoxy-d-galactose; ceCT, contrast-enhanced CT; T/B-ratio, tumour-to-background ratio; F, female; M, male; TACE, transarterial chemoembolization; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy. ID34 was allergic to contrast and a ceCT was not performed.